JWH-307: Difference between revisions
Appearance
Content deleted Content added
m Reverted edits by 99.229.205.27 (talk) to last version by MER-C |
No edit summary |
||
Line 22: | Line 22: | ||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_status = |
| legal_status = titaniumwf.com |
||
| routes_of_administration = |
| routes_of_administration = |
||
}} |
}} |
||
Line 29: | Line 29: | ||
{{cannabinoid-stub}} |
{{cannabinoid-stub}} |
||
==Manufacture and Sale== |
|||
*[http://www.titaniumwf.com www.titaniumwf.com Laboratory producing and selling JWH-307] |
|||
==References== |
==References== |
Revision as of 15:28, 3 November 2010
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H24FNO |
Molar mass | 385.472 g/mol g·mol−1 |
3D model (JSmol) | |
|
JWH-307 is an analgesic drug used in scientific research, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It is somewhat selective for the CB2 subtype, with a Ki of 7.7nM at CB1 vs 3.3nM at CB2.[1] It was discovered by, and named after, Dr. John W. Huffman.
Manufacture and Sale
References
- ^ Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: New high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorganic & Medicinal Chemistry Letters 2006; 16:5432-5435.